Prostat Kanseri: Bir Halk Sağlığı Sorunu
Özet
Prostat kanseri (PKa), erkekler arasında oldukça yaygın görülen bir sağlık sorunudur. Erken tanı küratif tedavi şansını artırır. Bu derleme çalışmasının amacı, PKa hakkında genel bir bilgi sunmak, toplum sağlığı üzerindeki etkilerini incelemek ve bu sorunun üstesinden gelmek için mümkün olan çözüm yollarını araştırmaktır. Çalışma için literatür verileri titizlikle incelenmiş ve bu veriler amacına uygun olarak sentezlenmiştir. Bireylerin ve toplumun sağlığını korumak için PKa ile ilgili bilinçli olmak, farkındalık oluşturmak ve risk faktörlerini azaltmak önemlidir.
Prostate cancer (PCa) is a common health issue among men. Early diagnosis increases the chances of curative treatment. The purpose of this review study is to provide general information about PCa, examine its impact on public health, and explore possible solutions to overcome this problem. Literature data has been meticulously reviewed for this study, and these data have been synthesized accordingly. Being conscious of PCa, raising awareness, and reducing risk factors are important to protect both individuals' and society's health.
Referanslar
John, H.A. and J.H. Guyton, Textbook of medical physiology. Saunders, Mississippi, 2013. p. 996-1009
Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2018. 68(6): p. 394-424.
Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü. 2018 Kanser İstatistikleri. Erişilebilir: https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri [01.09.2023]
Pentyala SN, Lee J, Hsieh K. Prostate Cancer: A Comprehensive Review. Medical Oncology. 2000; 17: 85-105.
IARC, Data visualization tools for exploring the global cancer burden in 2020. Erişilebilir: https://gco.iarc.fr/today/home [01.09.2023].
Yamamoto S, Senzaki A, Yamagiwa. Prostatic carcinoma in a young adult: a case report. Hinyokika Kiyo. 1990 May;36(5):617-22. Japanese. PMID: 1698013.
Gupta S, Gupta A, Saini AK. Prostate Cancer: How Young is too Young? Curr Urol. 2017 Jan;9(4):212-215. doi: 10.1159/000447143. Epub 2016 Dec 26. PMID: 28413383; PMCID: PMC5385860.
Perdana NR, Mochtar CA, Umbas R. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. Acta Med Indones. 2016 Jul;48(3):228-238. PMID: 27840359.
Stewart RW, Lizama S, Peairs K. Screening for prostate cancer. Semin Oncol. 2017 Feb;44(1):47-56. doi: 10.1053/j.seminoncol.2017.02.001. Epub 2017 Feb 11. PMID: 28395763.
Lynch, H.T, Kosoko-Lasaki O, Leslie SW. Screening for familial and hereditary prostate cancer. International journal of cancer, 2016. 138(11): p. 2579-2591
Ewing, C.M, Ray AM, Lange EM. Germline mutations in HOXB13 and prostate-cancer risk. New England Journal of Medicine, 2012. 366(2): p. 141-149.
Wein, AJ, Kavoussi, LR, Partin, AW. Campbell-Walsh urology: expert consult premium edition: enhanced online features and print, 4-volume set. 2011: Elsevier Health Sciences. Philadelphia, PA p.2704-2726
Bell, K.J, Del Mar C, Wright G. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. International journal of cancer, 2015. 137(7): p. 1749-1757.
Chin HW, Kim J, Rasp G. Prostate Cancer in Seniors: Part 1: Epidemiology, Pathology, and Screening. Fed Pract. 2015 May;32(Suppl 4):41S-44S. PMID: 30766120; PMCID: PMC6375450.
Center, M.M, Jemal A, Lortet-Tieulent J. International variation in prostate cancer incidence and mortality rates. European urology, 2012. 61(6): p. 1079-1092.
Baltacı, S., Gökçe, İ. Prostat Kanseri. Anafarta,K., Bedük, Y., Arıkan, N. (Ed.). (2011). Temel üroloji. Güneş Kitabevi p. 792-820
Anafarta, K., M. Baykara, and C. Baydinç, Ürogenital organların anatomik ve histolojik yapısı. Temel Üroloji, 1998. 4: p. 1-2.
Chen P, Zhang W, Wang X. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Aug;94(33):e1260. doi: 10.1097/MD.0000000000001260. PMID: 26287411; PMCID: PMC4616444.
Villa-Vásquez SS, Márquez-Fernández ME, Camargo-Guerrero M: Cytotoxic and genotoxic activity of omega fatty acids in prostate Cancer Cells PC-3. Iatreia 2018, 31(4): 351-361.
Matsushita M, Fujita K, Nonomura N. Influence of Diet and Nutrition on Prostate Cancer. International Journal of Molecular Sciences. 2020; 21(4):1447. https://doi.org/10.3390/ijms21041447
Balic I, Graham ST, Troyer DA. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. The Journal of urology, 2002. 168(5): p. 2245-2248.
Brawley, O.W., Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr, 2012. 2012(45): p. 152-6.
Grayhack JT, Bockrath JM. Diagnosis of carcinoma of prostate. Urology 1981;17(Suppl 3):54-60.
Catalona, W., Management of prostate cancer. N Engl J Med, 1994. 331: p. 996-1004.
Ayyıldız, S.N, A. Ayyıldız, PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Turkish journal of urology, 2014. 40(2): p. 82.
Günay, L.M., S. Yazıcı, H. Özen, PSA nereden geldi nereye gidiyor? Üroonkoloji Bülteni 2011. 2: p. 5.
Catalona, W.J., D.S. Smith, D.K. Ornstein, Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. Jama, 1997. 277(18): p. 1452-1455.
Oesterling, J.E, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. Jama, 1993. 270(7): p. 860-864.
Thompson, I.M, Pauler DK, Goodman PJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med, 2004. 350(22): p. 2239-46.
European Association of Urology. (2023). EAU Guidelines. Erişilebilir: http://www.uroweb.org/guidelines/ [01.09.2023].
Komura K, Sweeney CJ, Inamoto T. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018 Mar;25(3):220-231. doi: 10.1111/iju.13512. Epub 2017 Dec 20. PMID: 29266472; PMCID: PMC6053280.
Mottet N, van den Bergh RCN, Briers E. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. European urology, 2021. 79(2): p. 243-262.
Bill-Axelson A, Holmberg L, Garmo H. Radical prostatectomy or watch20ful waiting in prostate cancer—29-year follow-up. New England Journal of Medicine, 2018. 379(24): p. 2319-2329.
Bianco Jr FJ, Scardino P, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology, 2005. 66(5): p. 83-94.
Coughlin GD, Yaxley JW, Chambers SK. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. The Lancet Oncology, 2018. 19(8): p. 1051-1060.
Murphy GP, Mettlin C, Menck H. National patterns of prostate cancer treatment by radical prostatectomy: Results of a survey by the American College of Surgeons Committee on Cancer. Journal of Urology, (1994).152: 1817.
Tutolo M, Briganti A, Suardi. Optimizing postoperative sexual function after radical prostatectomy. Ther Adv Urol. 2012 Dec;4(6):347-65. doi: 10.1177/1756287212450063. PMID: 23205061; PMCID: PMC3491757.
Peeters S, Heemsbergen WD, Koper PC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol, 2006. 24(13): p. 1990-1996.
Scher HI, Morris MJ, Stadler WM. Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702.
Jakobsson L, Hallberg IR, Loven L. Experiences of dailylife and life quality in men with prostate cancer. An explorative study. Part I. Eur J Cancer Care 1997; 6:108-116
Anderson CA, Omar MI, Campbell SE. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev. 2015 Jan 20;1 (1):CD001843. doi: 10.1002/14651858.CD001843.pub5. PMID: 25602133; PMCID: PMC7025637.
Vartolomei L, Shariat SF, Vartolomei MD. Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. Eur Urol Oncol. 2018 Sep;1(4):283-291. doi: 10.1016/j.euo.2018.04.011. Epub 2018 May 15. PMID: 31100249.
